Press Releases

Press Releases

Email page PDF view Print view Email Alert Social media sharing

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
2/14/2017
7:02 AM ET
Press Release

RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board

2/14/2017

MARLBOROUGH, Mass., Feb. 14, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medica...

 Continue Reading
2/8/2017
7:02 AM ET
Press Release

RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences

2/8/2017

MARLBOROUGH, Mass., Feb. 8, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical...

 Continue Reading
2/7/2017
7:02 AM ET
Press Release

RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board

2/7/2017

MARLBOROUGH, Mass., Feb. 7, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical...

 Continue Reading
1/9/2017
7:02 AM ET
Press Release

RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer

1/9/2017

MARLBOROUGH, Mass., Jan. 9, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical...

 Continue Reading
12/26/2016
7:02 AM ET
Press Release

RXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™

12/26/2016

MARLBOROUGH, Mass., Dec. 26, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical nee...

 Continue Reading
12/21/2016
9:53 AM ET
Press Release

RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option

12/21/2016

MARLBOROUGH, Mass., Dec. 21, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical nee...

 Continue Reading
12/16/2016
8:15 AM ET
Press Release

RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering

12/16/2016

MARLBOROUGH, Mass., Dec. 16, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical nee...

 Continue Reading
12/13/2016
7:02 AM ET
Press Release

RXi Pharmaceuticals Provides Year End Update on its Business Development and Clinical Programs

12/13/2016

MARLBOROUGH, Mass., Dec. 13, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical nee...

 Continue Reading
Displaying 1 to 8 (of 151 releases)